SIGA Technologies (SIGA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

SIGA Technologies

NasdaqGM•Healthcare•Drug Manufacturers - Specialty & Generic

$3.20-0.09(-0.03%)Pre-market

Market Cap

$218.85M

P/S

4.1x

P/B

1.3x

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

How this company scores

AverageMetricSide Score: 40/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (2/25).

Profitability11/25

Growth2/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality12/25

Strengths

Long cash runwayInterest easily coveredCash-backed earningsNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.6x5y range 5.6x – 33.3x

Currently above its 18-quarter median.

P/S · 4.1x5y range 2.6x – 10.7x

Currently near its 20-quarter median.

P/B · 1.3x5y range 1.3x – 5.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 793.5% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $218.85M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $53.66M
Q. Revenue: $41.00M
TTM EBITDA: $-10.54M
TTM Op. Income: $-11.14M
Q. Op. Income: $13.91M
TTM Net Income: $-2.79M
Q. Net Income: $12.46M
EPS: $0.17
Shares Out.: $71.75M

$53.66M in TTM revenue declined 70.1% YoY, reaching $41.00M last quarter. TTM EBITDA of $-10.54M and TTM operating income of $-11.14M show growth is flowing through to the bottom line. However, net income is negative at $2.79M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 4 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 57.2%
EBITDA Margin: 34.6%
Op. Margin: 33.9%
Net Margin: 30.4%

Op. margin of 33.9% is down 22.4% YoY — costs are rising relative to revenue. Net margin at 30.4% and gross margin of 57.2% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 4.1x
P/B Ratio: 1.3x

P/S of 4.1x and P/B of 1.3x. Over the past year, P/E is up 131% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $175.74M
Cash: $117.58M
Long-Term Debt: N/A
Book Value: $165.29M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $15.17M
TTM Free Cash Flow: $-20.50M
FCF Margin: -38.2%
FCF / Net Income: 7.4

TTM FCF of $-20.50M on $15.17M in operating cash flow. The FCF / Net Income ratio of 7.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.